期刊文献+

微小核糖核酸-372在原发性肺癌组织中的表达水平及临床意义 被引量:1

Expression level and clinical significance of microRNA-372 in primary lung cancer tissues
下载PDF
导出
摘要 目的探讨原发性肺癌组织中微小核糖核酸-372(miRNA-372)的表达水平及临床意义。方法选取肺癌患者75例,采用实时荧光定量PCR法检测患者癌组织及癌旁正常组织中miRNA-372的表达水平,比较不同临床特征患者的肺癌组织miRNA-372表达水平。结果肺癌组织中的miRNA-372相对表达量低于癌旁正常组织(P<0.05);肿瘤直径≥2 cm者、Ⅲ~Ⅳ期者癌组织中miRNA-372相对表达水平分别低于肿瘤直径<2 cm者、Ⅰ~Ⅱ期者(均P<0.05)。结论 miRNA-372在原发性肺癌组织中呈低表达,其可能与肺癌发生发展相关。 Objective To investigate the expression level and clinical significance of microRNA-372( miRNA-372) in primary lung cancer tissues. Methods Seventy-five patients with lung cancer were enrolled,and the expression levels of miRNA-372 in cancer tissues and adjacent normal tissues were detected by real-time fluorescent quantitative PCR. The expression levels of cancer tissues miRNA-372 were compared among the patients with different clinical features. Results The relative expression level of miRNA-372 in lung cancer tissues was lower than that in adjacent normal tissues( P〈0. 05). The relative expression levels of cancer tissues miRNA-372 in the patients with tumor diameter ≥2 cm or of stage Ⅲ-Ⅳ were lower than those in the patients with tumor diameter 2 cm or of stageⅠ-Ⅱrespectively( all P〈0. 05).Conclusion The expression of microRNA-372 is quite low in primary lung cancer tissues,which might be related to the occurrence and progression of lung cancer.
作者 黄斯阳 罗强 HUANG Si-yang;LUO Qiang(Department of Cardiothoracic Surgery,Minzu Hospital Affiliated to Guangxi Medical University,Nanning 530021,China)
出处 《广西医学》 CAS 2018年第13期1434-1436,共3页 Guangxi Medical Journal
关键词 原发性肺癌 微小核糖核酸-372 临床特征 Primary lung cancer microRNA-372 Clinical feature
  • 相关文献

参考文献10

二级参考文献84

  • 1温宗秋.放疗、化疗或放化联合治疗局部晚期非小细胞肺癌临床对照分析[J].中国肿瘤临床与康复,2005,12(5):456-458. 被引量:5
  • 2吴易阳,李岭.MicroRNA与肿瘤相关的信号转导通路[J].遗传,2007,29(12):1419-1428. 被引量:12
  • 3Johnson DH.Locally advanced,unresectable non-small cell lung cancer:new treatment strategies[J].Chest,2000,117(4 Suppl1):123S-126S.
  • 4Dillman RO,Herndon J,Seagren SL,et al.Improved survival in stage III non-small-cell lung cancer:seven-year follow-up of cancer and leukemia group B(CALGB)8433 trial[J].J Natl Cancer Inst,1996,88(17):1210-1215.
  • 5Sause WT,Scott C,Taylor S,et al.Radiation Therapy Oncology Group(RTOG)88-08 and Eastern Cooperative Oncology Group(ECOG)4588:preliminary results of a phaseⅢtrial in regionally advanced,unresectable non-small-cell lung cancer[J].J Natl Cancer Inst,1995,87(3):198-205.
  • 6Rakovitch E,Tsao M,Ung Y,et al.Comparison of the efficacy and acute toxicity of weekly versus daily chemoradiotherapy for non-small-cell lung cancer:a meta-analysis[J].Int J Radiat Oncol Biol Phys,2004,58(1):196-203.
  • 7Kubota K,Furuse K,Kawahara M,et al.Role of radiotherapy in combined modality treatment of locally advanced non-small-cell lung cancer[J].J Clin Oncol,1994,12(8):1547-52.
  • 8TARVER T. Cancer Facts & Figures 2012. American Cancer Society(ACS) [ J ]. J Consum Health Internet, 2012,16 (3) : 366-367.
  • 9WANG Q z,xu w, HABIB N. Potential uses of mi-croRNA in lung cancer diagnosis, prognosis, and therapy [ J ]. Curt Cancer Drug Targets, 2009,9 (4) : 572 - 594.
  • 10SCHE33"ER A J, LEUNG S Y, SOHN J J, et al. MicroRNA ex- pression profiles associated with prognosis and therapeutic out- come in colon adenocarcinoma [ J ]. JAMA, 2008,299 ( 4 ) : 425-436.

共引文献67

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部